This study is looking at how different factors might affect the success of a treatment called cyclophosphamide (Cy) after a stem cell transplant for leukemia. Researchers want to understand how your genes and your donor's genes (pharmacogenomics), how your body processes the drug (pharmacokinetics), and certain immune cells (T cell phenotypes) influence the treatment. The goal is to find ways to give cyclophosphamide more effectively, reducing side effects like graft-versus-host disease (GVHD) while still fighting the cancer. To do this, they will compare cyclophosphamide levels in your body (Cy cMax Values) about 24 months after transplant. You may be able to join if you are 18 years or older and have leukemia.

Study design

This is an observational study, meaning researchers will collect information without giving a specific treatment. It plans to include 120 participants.

What's involved

Buccal swabs (a cheek swab) will be collected from donors for genetic testing. Blood samples will be taken to measure drug levels before and after transplant.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, comparing Cy cMax Values, is measured approximately 24 months after transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.